Rapport Therapeutics, Inc. (Nasdaq: RAPP) was dropped from several Russell Growth Indices, including the Russell 2000 Growth Index, Russell 2500 Growth Index, Russell 3000 Growth Index, Russell 3000E Growth Index, and Russell Microcap Growth Index, effective June 30, 2025. This exclusion impacts the company's presence in these widely followed benchmarks.
Removal from these indices can lead to a decrease in institutional investment, as passive funds that track these indices may divest their holdings. This could potentially affect the liquidity and trading volume of Rapport's common stock.
The change in index inclusion reflects a re-evaluation of the company's market capitalization and growth characteristics by the index providers. Rapport continues to focus on its clinical development programs for central nervous system disorders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.